{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"36.0","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"CD3+ tumor infiltrating T cells post treatment compared with pre-treatment reported with a 95% confidence interval assessed by multiplex CD3+ tumor infiltrating lymphocytes assessed by multiplex immunofluorescence from the surgical/ biopsy tissue collected pre- and post-treatment. The percentage of participants with doubling of baseline CD3+ tumor infiltrating lymphocytes will be provided as well as the 95% confidence interval. The CD3 cells are assessed by multiplex immunofluorescence in the biopsies. Doubling is the desired outcome.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II in newly diagnosed, untreated, locoregional p16-positove oropharyngeal cancer (OPC) (cohort 2) and in newly diagnosed. Arm 2A: HPV vaccine at recommended phase 2 dose (RP2D) as determined at completion of Arm 1A. HPV vaccine at 5x10\\^11 Viral Particles (VP).","id":"OG000","title":"Phase II Cohort 2, Arm 2A, Dose Level 2"}],"paramType":"NUMBER","populationDescription":"16/22 participants were evaluable because they received two treatments and had adequate biopsies.","reportingStatus":"POSTED","timeFrame":"Pre-Treatment (Baseline) and anytime between Week 4-5 post treatment","title":"Phase II: Percentage of Participants That Had a 2-fold Increase of Cluster of Differentiation 3 (CD3+) Tumor Infiltrating T Cells in Biopsies Performed Post-treatment Compared to Pre-treatment","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}